SCS Capital Management LLC acquired a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 53,430 shares of the company’s stock, valued at approximately $1,586,000. SCS Capital Management LLC owned 0.08% of Bicara Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Deutsche Bank AG raised its position in shares of Bicara Therapeutics by 0.9% during the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after purchasing an additional 1,171 shares during the last quarter. Legal & General Group Plc raised its stake in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Mariner LLC raised its stake in Bicara Therapeutics by 3.0% in the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock valued at $1,087,000 after purchasing an additional 1,902 shares during the last quarter. Invesco Ltd. lifted its holdings in Bicara Therapeutics by 13.2% in the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after purchasing an additional 1,962 shares in the last quarter. Finally, Quantinno Capital Management LP boosted its stake in Bicara Therapeutics by 16.1% during the 1st quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock worth $350,000 after purchasing an additional 2,447 shares during the last quarter.
Bicara Therapeutics Price Performance
NASDAQ:BCAX opened at $24.28 on Monday. The company’s 50-day moving average is $26.15 and its two-hundred day moving average is $21.84. Bicara Therapeutics Inc. has a 1-year low of $10.30 and a 1-year high of $30.99. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -7.83 and a beta of -0.75.
Insider Buying and Selling at Bicara Therapeutics
In related news, CEO Claire Mazumdar sold 10,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $279,800.00. Following the completion of the transaction, the chief executive officer owned 362,152 shares of the company’s stock, valued at approximately $10,133,012.96. This trade represents a 2.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 18,750 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $524,625.00. Following the completion of the sale, the chief operating officer owned 181,641 shares of the company’s stock, valued at $5,082,315.18. This trade represents a 9.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 117,200 shares of company stock worth $3,267,100 over the last quarter. 13.80% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
BCAX has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. Morgan Stanley increased their price objective on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. The Goldman Sachs Group boosted their target price on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday. Mizuho upped their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Wells Fargo & Company increased their price target on Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.73.
Check Out Our Latest Report on Bicara Therapeutics
Bicara Therapeutics Profile
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Featured Articles
- Five stocks we like better than Bicara Therapeutics
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
